Cell therapy for muscular dystrophies: advances and challenges.
about
Oxidative Stress-Mediated Skeletal Muscle Degeneration: Molecules, Mechanisms, and TherapiesRecent progress in satellite cell/myoblast engraftment -- relevance for therapyPericytes: multitasking cells in the regeneration of injured, diseased, and aged skeletal muscle.Electroporation as a method to induce myofiber regeneration and increase the engraftment of myogenic cells in skeletal muscles of primates.Cell therapy in muscular dystrophies: many promises in mice and dogs, few facts in patients.Successful regional delivery and long-term expression of a dystrophin gene in canine muscular dystrophy: a preclinical model for human therapies.Skeletal muscle α-actin diseases (actinopathies): pathology and mechanisms.Invited review: Stem cells and muscle diseases: advances in cell therapy strategies.Polydopamine-Decorated Sticky, Water-Friendly, Biodegradable Polycaprolactone Cell Carriers.Post-natal induction of PGC-1α protects against severe muscle dystrophy independently of utrophin.Beneficial effect of mechanical stimulation on the regenerative potential of muscle-derived stem cells is lost by inhibiting vascular endothelial growth factor.The Process of Engraftment of Myogenic Cells in Skeletal Muscles of Primates: Understanding Clinical Observations and Setting Directions in Cell Transplantation Research.Hydrogel biomaterials and their therapeutic potential for muscle injuries and muscular dystrophies.Ecto-mesenchymal stem cells from facial process: potential for muscle regeneration.De Novo Circulating Antidonor's Cell Antibodies During Induced Acute Rejection of Allogeneic Myofibers in Myogenic Cell Transplantation: A Study in Nonhuman Primates.Translational Research in Stem Cell Treatment of Neuromuscular Diseases
P2860
Q26769962-D5D81AC1-9D83-4C0D-895E-03D0512D49A5Q27014183-4B4FDDE9-29E3-482A-B3C4-C1B8C59EEF2AQ34201678-C144523C-A100-4A2D-B1C6-5DAC9B3562F5Q34823922-0B91C05B-7D47-4E6F-8157-256E7C174EA1Q35664379-DFCD9477-3019-4981-B0F4-E3E31564E26AQ36142496-0DD7E3CE-2D72-47C8-A057-F079EEF777A0Q38028847-A8D5B286-DA02-426B-AF0F-FDF984AE47FEQ38269131-1B131372-6AE0-4301-B0EC-A435EE464BE7Q40074033-47CF1939-3B87-4098-BB7A-7D94C3BE29CEQ41911490-F1F6C348-64D9-4DB3-9548-7135347A8104Q41912624-B3EDCFAF-8BC5-4A95-84E0-50AEB831C572Q47729696-016AA0F0-78E2-4A30-B3CF-ECED5C197489Q48223753-834C07C1-046B-4ECA-BD21-F133782FEDBEQ53570293-8789EF32-633F-48D6-9549-3725B339362CQ55272718-D20E4D23-8296-45E3-8A29-EB4329A1E6D5Q59001351-612F01D3-AC66-4F7C-9312-A4417C884776
P2860
Cell therapy for muscular dystrophies: advances and challenges.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Cell therapy for muscular dystrophies: advances and challenges.
@en
Cell therapy for muscular dystrophies: advances and challenges.
@nl
type
label
Cell therapy for muscular dystrophies: advances and challenges.
@en
Cell therapy for muscular dystrophies: advances and challenges.
@nl
prefLabel
Cell therapy for muscular dystrophies: advances and challenges.
@en
Cell therapy for muscular dystrophies: advances and challenges.
@nl
P1476
Cell therapy for muscular dystrophies: advances and challenges
@en
P2093
Cyril Catelain
Karine Vauchez
P304
P356
10.1097/MOT.0B013E32834CFB70
P577
2011-12-01T00:00:00Z